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precede biopsy.1,2 In fact, the 14 men who underwent prebiopsy mpMRI in this cohort were excluded from further
analysis. The authors acknowledge postbiopsy hemorrhage
contributed to disease inconspicuity in approximately onethird of men (2−3/9) with high-grade disease, however,
given this well-established phenomenon, this proportion
may be higher.5 As postbiopsy hemorrhage was accepted
and incorporated into this study, it is possible that other
radiological features (eg, background patchy/diffuse patterns) may have contributed to reduced tumor conspicuity.
In addition to mpMRI quality, other aspects of this study
warrant scrutiny. Of note, 45% (15/33) of men had grade
reclassiﬁcation from random 12-core transrectal ultrasound
(TRUS)-guided biopsy to radical prostatectomy (18%
downgraded, 27% upgraded). This effect may be attributable to an imperfect reference standard (random TRUSguided biopsy) which demonstrably overlooks signiﬁcant
cancer approximately half the time.2 Furthermore, while
mpMRI were scored according to PI-RADSv2.1 guidelines,
it seems unusual that men with “negative” mpMRI had
such high prostate speciﬁc antigen densities (eg, 1.08, 0.48,
and 0.22 ng/mL/mL) which, in other settings, may have
raised radiological suspicion. Unfortunately, a number of
key details are missing to fully appraise this study including,
biopsy core length, tumor size at prostatectomy, age of MRI
machines, number of reporting radiologists and their experience in prostate mpMRI reporting (ie, how many prostate
MR scans per year), all of which impact upon tumor detection on mpMRI. Lastly, in their discussion, the authors cite
the Prostate MRI Study (PROMIS), proposing that a 10%
nondetection rate of signiﬁcant disease by mpMRI is a
“considerable risk,” however, they do not quote the false
negative rate of systematic TRUS-guided biopsy (their own
reference standard), which had a nondetection rate of over
50%, in the same study.2
Collectively, we should work toward optimal mpMRIdirected pathway delivery, at every juncture, including
scan acquisition, reporting, and biopsy. In an attempt to
standardize mpMRI quality, the Prostate Imaging Quality
(PI-QUAL) score was developed, based on a 1-to-5 Likert
scale derived from evaluation of each sequence, against
objective quality criteria in line with the PI-RADSv2 recommendations.4 Work is currently underway to evaluate
effects of PI-QUAL on tumor conspicuity, however, we
hope that this scheme provides a starting point for centers
to evaluate quality of mpMRI delivery. Alanee et al
should be congratulated for adding to the mpMRI literature, expounding links between histopathology and radiology, however, we believe their ﬁndings should be
cautiously interpreted in light of the methodological issues
highlighted here. We agree that long-term ramiﬁcations of
mpMRI conspicuity remain pressing avenues for future
research and we eagerly await results of ongoing work.
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AUTHOR REPLY
We thank the authors of this intriguing letter for their signiﬁcant interest in our work. They raise essential points
that we would like to respond to in detail. The authors' ﬁrst
concern was that, contradictory to "guidelines", the magnetic resonance imaging (MRI) studies included in our
analysis were done after prostate cancer was diagnosed with
a biopsy, causing bleeding and making it harder to visualize
the tumor inside the prostate. The patients included in our
study were prostate cancer patients receiving MRI for surgical planning. The “guidelines” the authors refer to is for
patients with elevated prostate speciﬁc antigen (PSA).
Besides, our pathology coauthors (2 fellowship-trained genitourinary pathologists) characterized the tumors that were
not visible on MRI and did not notice signiﬁcant bleeding
in the areas of interest.
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The authors' second concern was that the reference for
upgrading was the random 12-core transrectal ultrasound
(TRUS) biopsy. We agree with them that a random
TRUS biopsy could underestimate the grade of prostate
cancer. However, this study's goal was to characterize
MRI invisible tumors, not to look into reasons for upgrading from TRUS biopsy on postprostatectomy pathology,
which has been examined by many other papers. We also
agree with others that TRUS-biopsy has a high nondetection rate, and we are not advocating against MRI of the
prostate in favor of TRUS-guided biopsy. In fact, in the
editorial comment we wrote to accompany our paper, we
state that MRI provides "essential information during
prostate cancer management." Still, we call on providers
to consider other clinical variables when interpreting
MRI results. The authors mention that elevated PSA density would have made the radiologist suspicious that their
MRI may be missing signiﬁcant cancer, which supports
paying attention to clinical variables while MRI technology continues to evolve.
Finally, we would like to highlight 2 recent papers that
support our conclusions. In a recent report by Ahdoot et
al in the New England Journal of Medicine, 2103 men with
MRI-visible prostate lesions underwent both MRI-targeted and systematic biopsies. A proportion of them then
received treatment with radical prostatectomy. Ahdoot et
al then showed that MRI-targeted biopsies misclassiﬁed
8.8% of clinically signiﬁcant cancers.1 Separately,
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Westphalen et al conducted a retrospective cross-sectional
study across 26 centers treating prostate cancer to estimate
the positive predictive value (PPV) of PI-RADS to detect
high-grade prostate cancer. The authors estimated the
PPV to be 35% for PI-RADS ≥ 3 and 49% for PI-RADS
≥ 4. The interquartile ranges of PPV at these same PIRADS score thresholds were 27%-44% and 27%-48%,
respectively. They then concluded that the PPV of the
PI-RADS was low and varied widely across centers.2
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